ADHD treatment in Eatontown, New Jersey

ADHD (Attention-Deficit/Hyperactivity Disorder) is a neurodevelopmental condition that affects attention, impulse control, and executive function — the brain's ability to plan, prioritize, and follow through. The DSM-5-TR — the current diagnostic manual — defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning, with several symptoms present before age 12 and in two or more settings (work, home, school, social).

About 4.4% of U.S. adults have ADHD, per NIMH data. Pediatric prevalence is higher — approximately 11% of children — and most adult cases originated in childhood, even when the diagnosis came later. Many adults were never identified in childhood because their symptoms didn't include obvious hyperactivity or because compensation strategies hid the underlying pattern.

The condition is real, well-characterized, and treatable. ADHD is among the most-studied psychiatric conditions in modern medicine. The neurobiological basis (differences in dopamine and norepinephrine signaling, prefrontal cortex development, default-mode network regulation) is well-established. Treatment works for most patients, though "works" looks different across individuals.

We don't diagnose in copy on a website. The criteria below help you frame what you're noticing. The diagnosis itself is made through a clinical evaluation — for adults, typically a 90-minute initial session that includes a structured interview, standardized rating scales (Conners Adult ADHD Rating Scale or BASC are common), and review of childhood symptoms when accessible. Self-report alone isn't enough. Multi-informant data (a partner, a parent, school records) strengthens the assessment when it's available.

What separates ADHD from typical attention difficulty: the persistence (since childhood, in most cases), the multi-setting pattern, the functional impairment, and the response to ADHD-specific treatment when applied. "I have a hard time focusing at meetings" alone isn't ADHD. A pattern of inattention and/or hyperactivity-impulsivity across years and settings, that affects how you function, may be.

The DSM-5-TR recognizes three ADHD presentations based on which symptoms predominate. The presentation can shift over the lifespan; many people who were predominantly hyperactive-impulsive as children become predominantly inattentive as adults.

Predominantly inattentive presentation. What used to be called "ADD." Difficulty sustaining attention, organizing tasks, finishing what you start. Inattentive ADHD is often missed in childhood — particularly in girls and high-achieving students — because the symptoms don't disrupt others. Many adults discovering ADHD later in life were inattentive children whose ability to compensate hit a ceiling under adult demands.

Predominantly hyperactive-impulsive presentation. Restlessness, fidgeting, talking excessively, difficulty waiting turn, impulsive decisions. More often identified in childhood because the symptoms are externally visible. In adults, hyperactivity often becomes internal — a sense of restlessness rather than visible motor activity — while impulsivity may persist.

Combined presentation. Symptoms from both clusters. The most-recognized form publicly and clinically common in childhood. In adults, the mix shifts.

Adult ADHD specifically. Adults discovering ADHD later in life often present differently than the textbook-pediatric picture. Some patterns we see frequently:

• Years of compensation through over-effort. Building elaborate systems to manage what should come naturally; spending evenings and weekends catching up on what didn't fit during the day; sustained reliance on caffeine, structure, or external pressure to function.
• Late diagnosis after burnout. Compensation has a ceiling. Many adults seek evaluation after a job change, a child's diagnosis, a relationship strain, or a period of executive-function collapse.
• Late diagnosis in women specifically. Women and girls are diagnosed with ADHD at substantially lower rates in childhood than boys. The inattentive presentation, social masking, and gendered expectations all contribute. Many women come to evaluation in their 30s or 40s.
• Rejection-sensitive dysphoria (RSD). Not a DSM-5-TR diagnosis, but a clinically meaningful pattern in many adults with ADHD: intense emotional pain triggered by perceived rejection or criticism. RSD doesn't appear in formal criteria but informs how we think about treatment.
• Time blindness and task initiation difficulty. Two of the most-cited subjective experiences of adult ADHD — disconnection from time as a felt quantity, and the gap between knowing what to do and being able to start.

A late diagnosis isn't a sign that you "should have figured this out years ago." Most adults with ADHD adapted well enough that no one — including themselves — thought to ask. The diagnosis explains a pattern, opens treatment options, and isn't a verdict on prior coping.

Most adults who eventually seek ADHD evaluation noticed something for years before they called. The reasons vary. Some were told their symptoms were anxiety, depression, or "just personality." Some were skeptical that their pattern fit a diagnosis after a lifetime of getting by. Some saw their child get diagnosed and recognized themselves.

The threshold for seeking evaluation isn't "I meet exactly six DSM criteria." It's simpler. Have attention, organization, or impulse-control patterns affected your work, relationships, or self-image since childhood? Are they getting harder rather than easier under adult demands? If yes, evaluation is worth doing. The result might be ADHD; it might be something else. Either way, you'll know more than you do now.

What an evaluation looks like at our clinic. The first visit is a 90-minute session with a clinician. We use a structured interview, standardized rating scales (typically the Conners Adult ADHD Rating Scale or BASC-3 self-report), and a careful review of developmental history — what was childhood like at school, at home, in extracurriculars. When relevant, we collect collateral information from a partner, parent, or school records. We rule out conditions that can mimic ADHD: thyroid disorders, sleep apnea, untreated depression or anxiety, substance use. We screen for comorbidities that often accompany ADHD (anxiety, depression, learning disorders).

The list below collects symptoms patients commonly bring to a first ADHD-focused visit. It's not a diagnostic tool. If several resonate and have been present since childhood, that's information worth bringing to an evaluation.

Medication is the most-evidenced treatment for ADHD. Stimulants are first-line for most adult patients; non-stimulants are first-line for some. The right choice depends on response, side effect tolerance, comorbidity, and individual factors including substance-use history.

Stimulants — first-line. Two classes are FDA-approved for adult ADHD:

• Methylphenidate-class. Methylphenidate (Ritalin), extended-release methylphenidate (Concerta), dexmethylphenidate (Focalin). Different formulations cover different durations of effect — 4 hours for immediate-release, up to 12 hours for some extended-release products.
• Amphetamine-class. Mixed amphetamine salts (Adderall, Adderall XR), lisdexamfetamine (Vyvanse), dextroamphetamine (Dexedrine). Vyvanse has the longest duration (12+ hours) and lower abuse potential than immediate-release Adderall because it's a prodrug — converted to active form in the body.

Both classes work for most ADHD patients. Individual response varies. Many patients try one class, find it doesn't fit (side effects, response curve, peak-and-crash pattern), and respond better to the other. Switching between classes after an initial trial is normal clinical practice.

Stimulants work fast. Most patients notice the effect within 30 to 60 minutes of the first dose. The dose is titrated upward over a few weeks to find the lowest effective dose. Common side effects include appetite suppression, sleep disruption (if taken too late in the day), increased heart rate, dry mouth, and — for some patients — anxiety or irritability. Most side effects are dose-related and adjustable.

Stimulants are Schedule II controlled substances. This means stricter prescribing rules, monthly refills (no automatic 90-day supply), and required pharmacy interactions. We use New Jersey's Prescription Monitoring Program (PMP) to coordinate care safely. The DEA also requires in-person evaluation before stimulant prescribing in most cases — telehealth-only stimulant prescribing has become more restricted post-2024. We can do the evaluation either in person at our Eatontown office or via a hybrid telehealth + initial in-person visit.

Non-stimulants — first-line for some patients. Non-stimulants are appropriate when stimulants haven't worked, weren't tolerated, or aren't a good fit because of substance-use history, cardiovascular concerns, or patient preference.

• Atomoxetine (Strattera). A norepinephrine reuptake inhibitor specifically FDA-approved for ADHD. Onset is slower than stimulants — typically 4 to 8 weeks for full effect. Generally well-tolerated.
• Bupropion (Wellbutrin). Used off-label for ADHD with reasonable evidence. Dual-action on dopamine and norepinephrine. Often a good fit when ADHD coexists with depression.
• Guanfacine (Intuniv) and clonidine. Originally blood-pressure medications, used for ADHD primarily in pediatric patients but sometimes in adults. Useful for patients with prominent emotional dysregulation or sleep disruption.

The honest framing. Stimulants reduce ADHD symptoms substantially in roughly 70 to 80% of adult patients who get an adequate trial. They don't replace the work of building executive-function skills (Section 5). The combination of medication plus skills work outperforms either alone.

For ongoing prescribing and adjustment, see our medication management page. For the initial evaluation that determines whether ADHD is the diagnosis and what medication fits, see psychiatry.

Therapy for ADHD doesn't replace medication. Medication doesn't replace therapy. The combination of medication plus skills-focused therapy outperforms either alone for most adults. The therapy work targets executive function specifically — the skills medication doesn't directly teach.

CBT for ADHD. Adapted from standard CBT to address ADHD-specific patterns: planning and time estimation, breaking tasks into actionable steps, building external supports for working memory, addressing the avoidance and procrastination that have accumulated over years. CBT for adult ADHD typically runs 12 to 20 weekly sessions of about 50 minutes each. Best evidence is for executive-function skills, organization, and reducing the compensation overload that drove many adults to seek treatment.

Executive-function coaching. Often delivered alongside CBT or as a standalone option for patients whose primary need is practical-skills work. Coaching focuses on systems — calendar use, task management, environmental setup, accountability structures — that externalize what's hard to do internally with ADHD. Coaching is generally not insurance-covered the way therapy is, and many patients combine therapy through insurance with coaching paid out of pocket.

Mindfulness-based approaches. Mindfulness-based attention training has growing evidence in ADHD, particularly for emotional dysregulation and reactive impulsivity. We integrate mindfulness elements into CBT for ADHD when patient interest aligns.

Addressing comorbidity. Many adults with ADHD also meet criteria for depression, anxiety, or both. The order of treatment depends on severity. When depression or anxiety is severe enough that it's the primary obstacle, we treat it first or in parallel; when the ADHD is what's driving the comorbid pattern, treating ADHD often improves the comorbidity. See our depression page and anxiety page for the broader frameworks.

What to expect in early sessions. The first 2 to 4 sessions are typically about pattern-mapping (where do attention, organization, and impulse control break down for you specifically), building a working framework, and starting low-effort experiments. Treatment isn't about "trying harder" — that's exactly what hasn't worked. It's about building structures that make working with your brain easier than working against it.

Comorbidity is the rule for adult ADHD, not the exception. Most adults seeking ADHD evaluation also meet criteria for at least one other condition. The most common patterns:

ADHD + depression. Roughly 30 to 50% of adults with ADHD also have major depression at some point. The conditions interact: years of ADHD-related underperformance, missed deadlines, and self-criticism contribute to depression; depression worsens executive function and motivation. Treating one without the other typically falls short. We address both together when both are present.

ADHD + anxiety. Even more common — roughly half of adults with ADHD also have an anxiety disorder. The patterns vary: some patients have anxiety as a downstream consequence of ADHD-related stress; others have a primary anxiety disorder that ADHD complicates. Treatment depends on which is driving more of the impairment.

ADHD + substance use. Higher prevalence than in the general population — roughly 1 in 4 adults with ADHD has a substance-use disorder at some point. Stimulant medication for ADHD does not, on average, increase substance-use risk in patients with appropriate diagnosis and prescribing; some research suggests it may modestly reduce risk by addressing the underlying ADHD. That said, we screen carefully, prescribe deliberately, and consider non-stimulants when substance-use history warrants. Joseph Vacchiano on our team is dual-licensed as an LCADC and works with patients in this combination regularly.

ADHD + sleep disorders. Sleep is unusually disrupted in adult ADHD. Delayed sleep phase (going to bed too late and getting up too late) and insomnia (especially at sleep onset) are common. Stimulant timing matters — taking medication too late in the day worsens sleep. We address sleep directly as part of treatment.

ADHD + autism spectrum disorder. Increasingly recognized comorbidity. Adults with both conditions often have a complicated diagnostic history because symptom overlap and compensation patterns vary. Diagnosis benefits from clinicians experienced in both presentations; we coordinate with autism-specific evaluation when warranted.

ADHD + bipolar disorder. A more complex distinction because hypomanic features can resemble ADHD energy and impulsivity. Careful diagnosis matters because stimulants can destabilize mood in bipolar disorder. When both are present (it does happen), the bipolar condition is stabilized first; ADHD treatment is added carefully. See our bipolar disorder page for that framework.

The point: most ADHD treatment plans address more than just ADHD. We coordinate care across these threads instead of asking you to manage them in separate offices.

ADHD often begins in childhood — by definition, several symptoms must be present before age 12 — but the way it presents in pediatric patients differs from adult presentations.

In children, hyperactive-impulsive features are often more prominent: restless motor activity, difficulty waiting, impulsive responses. Pediatric inattentive symptoms are more easily missed because they don't disrupt others. Girls and high-functioning students are particularly at risk for late or missed diagnosis in childhood.

Treatment for pediatric and adolescent ADHD draws on the same evidence base as adult ADHD. Stimulants are first-line; methylphenidate-class is more often used in younger children, with amphetamine-class used in older adolescents and adults. Non-stimulants — particularly guanfacine and atomoxetine — have meaningful pediatric evidence and are used commonly. Behavior therapy with parent training is the recommended first-line treatment for preschool-age ADHD and is added to medication for school-age children.

For teen-specific care patterns — including school accommodation work, family coordination, and the late-childhood/early-adolescent transition — see our teen ADHD page.

If you're an adult discovering ADHD in your own children's evaluation process, that's common — ADHD has high heritability, and a child's diagnosis sometimes prompts the parent's own. Both can be evaluated and treated; the practical sequencing depends on what's most pressing for your family.

Honest answer: ADHD is a long-term condition, and most adults benefit from continued treatment over years rather than a defined finish line. The treatment timeline is measured in stability and improved functioning, not in months to a stop date.

Initial medication titration. 4 to 8 weeks to settle on the right medication and dose. Most patients try one or two stimulants before finding the fit; some need longer.

Therapy course. CBT for adult ADHD typically runs 12 to 20 weekly sessions. Skills work continues to be useful long after the structured course ends; many patients do periodic check-in sessions over the years.

Ongoing medication management. Once a stable medication regimen is established, follow-up visits are typically every 8 to 12 weeks. Dose adjustments are common over time — life changes, work demands, sleep patterns, and aging all affect how medication works. Stimulant prescribing requires monthly refills; we structure visits to make that workable rather than disruptive.

Long-term outcomes. Adults with treated ADHD do better than adults with untreated ADHD across nearly every measurable outcome — work performance, relationships, financial stability, mental health, accident rates. The treatment isn't curative; ADHD doesn't go away. The work is making the brain you have functional in the life you want.

We don't promise specific outcomes. We do measure progress with standardized tools (typically the Adult ADHD Self-Report Scale, ASRS) at regular intervals so we can see what's working and adjust if it isn't. For most patients, what shifts is not the disappearance of ADHD but a different relationship to it — fewer compensation costs, more sustainable systems, less self-criticism, and more energy left over for the parts of life that matter.